Compare ZKH & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZKH | ADCT |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.4M | 483.1M |
| IPO Year | 2023 | 2020 |
| Metric | ZKH | ADCT |
|---|---|---|
| Price | $3.39 | $3.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 174.8K | ★ 965.0K |
| Earning Date | 11-20-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,236,195,501.00 | $75,209,000.00 |
| Revenue This Year | $2.58 | $10.36 |
| Revenue Next Year | $10.62 | $3.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $2.50 | $1.05 |
| 52 Week High | $3.90 | $4.80 |
| Indicator | ZKH | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 49.88 |
| Support Level | $3.09 | $3.38 |
| Resistance Level | $3.56 | $3.89 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 35.19 | 68.81 |
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).